Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018
February 7, 2018 7:40 AM EST
Leerink Partners raised its price target on Array BioPharma (NASDAQ: ARRY) to $20.00 (from $19.00) while maintaining a Outperform rating.
...
More
February 7, 2018 7:05 AM EST
Cowen raised its price target on Array BioPharma (NASDAQ: ARRY) to $19.00 (from $17.00) while maintaining a Outperform rating.
Analyst Chris Shibutani commented, "F2Q18 results were highlighted by impressive pipeline updates including COLUMBUS data with greater than expected OS of 33.6 months for COMBO450 in BRAF-mutant... More
February 7, 2018 6:27 AM EST
Stifel raised its price target on Array BioPharma (NASDAQ: ARRY) to $23.00 (from $20.00) while maintaining a Buy rating.
Analyst Stephen Willey commented, "The disclosure of median OS data from the P3 COLUMBUS trial (encorafenib/binimetinib vs. vemurafenib in BRAF-mutant melanoma) provides further confirmation of the pharmacological... More
February 6, 2018 8:08 AM EST
Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $42.2 million versus the consensus estimate of $26.67 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
...
More
